Stories about HMOs

Subscribe to HMOs

22.09.2020 – 15:30

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market

Rheinbreitbach and Bonn, Germany (ots/PRNewswire) - Jennewein Biotechnologie GmbH agreed to join forces with Chr. Hansen Holding A/S, a leading bioscience company based in Hoersholm/Denmark, to lead the global market for human milk oligosaccharides (HMOs). Chr. Hansen entered into an agreement to acquire all shares ...

more
22.09.2020 – 15:30

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market

Rheinbreitbach/Bonn (ots) - Jennewein Biotechnologie GmbH agreed to join forces with Chr. Hansen Holding A/S, a leading bioscience company based in Hoersholm/Denmark, to lead the global market for human milk oligosaccharides (HMOs). Chr. Hansen entered into an agreement to acquire all shares in Jennewein ...

more
20.08.2020 – 16:21

Jennewein Biotechnologie GmbH
US Customs rules in favor of Jennewein Biotechnologie regarding importation of 2'-Fucosyllactose

RHEINBREITBACH, Germany (ots) - Jennewein Biotechnologie GmbH the leading manufacturer of human milk oligosaccharides (HMOs) in the world, announced today that the Intellectual Property Rights Branch, Regulations and Rulings, U.S. Customs and Border Protection issued a Ruling Letter which asserts that the HMO 2'-fucosyllactose (2'-FL) being produced by Jennewein ...

more
29.07.2020 – 15:00

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie GmbH announces the foundation of Jennewein Biotech Corp. USA

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, a market leading and science-based company for developing and producing human milk oligosaccharides (HMOs) and rare monosaccharides, announced today that it has established its subsidiary in the USA. Jennewein Biotech USA Corporation, a Delaware Corporation, utilizing warehouses in Chicago, IL and Columbus, OH, will ...

more
27.05.2020 – 11:00

Jennewein Biotechnologie GmbH
Jennewein publishes new results on the norovirus-inhibiting effect of complex oligosaccharides

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH today announces the publication of the latest results from its norovirus research program in the Journal of Biotechnology. Breast-fed infants are less likely than bottle-fed infants to contract norovirus infections, and earlier work has indicated a link between this protective effect and human milk oligosaccharides ...

more
20.05.2020 – 15:09

Jennewein Biotechnologie GmbH
Supply of Key Ingredient in advanced infant formula by Jennewein is secured

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, a worldwide leading manufacturer of human milk oligosaccharides (HMOs) announces today that the U.S. International Trade Commission (ITC) issued on May 19, 2020 a Final Determination finding that one of Jennewein's advanced bacterial production strains for producing 2'-fucosyllactose (2'-FL) does not infringe ...

more
08.01.2020 – 17:00

Jennewein Biotechnologie GmbH
Publication of a toxicological study: a milestone for Jennewein Biotechnologie for the GRAS approval of the HMO-mix

Rheinbreitbach (ots) - Jennewein Biotechnology announces another milestone in the Worldwide approval of a new product generation, the "HMO-Mix". The data of the toxicological study, with the title "A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats", was recently accepted for publication by the ...

more
25.11.2019 – 10:13

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie obtains US-FDA GRAS status on alternative 2'-fucosyllactose fermentation strain

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, Rheinbreitbach, the leading manufacturer of human milk oligosaccharides (HMOs), announces that the U.S. Food and Drug Administration (FDA) issued a "no question" response letter to Jennewein's supplement of its GRAS Notice GRN571, thereby acknowledging that the ...

more
25.11.2019 – 10:02

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie sues Glycom for patent infringement in Denmark

Rheinbreitbach (ots) - Jennewein Biotechnologie develops fermentative processes for manufacturing of human milk oligosaccharides (HMOs) cost efficiently in an industrial scale since 2005 to make these special sugars available for affordably priced infant formula and other uses in food. Jennewein Biotechnologie was the first commercial vendor of HMOs, and brought the ...

more
08.10.2018 – 14:00

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie GmbH acquires Arthus Mineralsprings Bad Hönningen to build a new integrated fermentation and recovery plant for human milk oligosaccharides

Rheinbreitbach/Germany (ots) - Jennewein Biotechnologie GmbH announces that it has acquired the former facilities of Arthus Mineralspring Company in Bad Hönningen (Rhineland-Palatine) in order to expand the production of human milk oligosaccharides (HMOs). "We have been searching for some time for a suitable ...

more
24.07.2018 – 12:00

Jennewein Biotechnologie GmbH
EIB provides funding to Jennewein

Rheinbreitbach (ots) - The European Investment Bank (EIB) provides new financing of EUR 15 million to Jennewein Biotechnologie GmbH, a highly innovative German company that offers a breakthrough technology for the production of rare functional sugars for a wide range of applications, including nutritional, pharmaceutical and cosmetic products. The Company is also a leading manufacturer of human milk oligosaccharides (HMOs), which form an essential part of human mother milk ...

more

1